Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19719051 | 0.86 | FTO (0.55) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL21309677 | 0.85 | FTO (0.58) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL31580193 | 0.84 | FTO (0.55) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL29383733 | 0.84 | FTO (0.55) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL334086 | 0.84 | FTO (0.55) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL1539101 | 0.82 | FTO (0.63) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL29579867 | 0.82 | FTO (0.55) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL23192496 | 0.81 | FTO (0.62) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL24736659 | 0.81 | FTO (0.62) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL20339897 | 0.81 | FTO (0.53) | FTOMAPTMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286285-B2 | Modified biotin, streptavidin mutant, and usage of them | SAVID THERAPEUTICS INC. (JP) | 2022-03-29 | — | — | US | disclosed |
| US-20170145063-A1 | MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM | SAVID THERAPEUTICS INC. (JP) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145063-A1 | MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM | BTD, HLCS, BROX | FTO 3439/4885MAPT 3919/4885MEN1 3172/4885 |
| US-11286285-B2 | Modified biotin, streptavidin mutant, and usage of them | BTD, HLCS, BROX | FTO 3439/4885MAPT 3919/4885MEN1 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.